Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity.


Journal

Clinical biochemistry
ISSN: 1873-2933
Titre abrégé: Clin Biochem
Pays: United States
ID NLM: 0133660

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 13 05 2020
revised: 13 07 2020
accepted: 16 07 2020
pubmed: 24 7 2020
medline: 29 9 2020
entrez: 24 7 2020
Statut: ppublish

Résumé

Since February 2020, Italian hospitals registered COVID-19 (COronaVIrus Disease 19) cases more often than the rest of the Europe. During this epidemic, health authorities requested swab tests, while seeking new patient paths. A dual laboratory approach was evaluated, consisting of patient care reports for viral RNA detection on swabs and rapid serological tests in 516 patients (192 symptomatic or paucisymptomatic and 324 asymptomatic). We found the molecular positive fraction equal to 12% (23/192) among symptomatic/paucisymptomatic (S/P) and 15.4% (50/324) in asymptomatic (As) sets. Among subsets, we observed serologically positive results, corresponding to 35% (8/23) for S/P and 38% (19/50) for As. Among molecular negative cases, we detected specific Immunoglobulin G or M (Ig G or Ig M) positivity in the S/P cohort equal to 6.6% (11/167) and 6% (15/246) in As cases. For indeterminate molecular results, we found S/P serological positivity equal to 100% (1/1) and 54% (13/24) in As patients. We found higher (p < 0.05) seropositivity in older patients (n = 8) among symptomatic and positives for viral RNA (n.23). It has been observed that a dual approach of serological and molecular tests detects a higher absolute number of disease cases in a pandemic context,which could improve monitoring and health surveillance efficacy. The age-related seropositivity frequency in this study, if confirmed, could enhance the validity of serological tests, especially in older patients.In these subjects, molecular positivity accompanied by serological positivity (distinct for M and G immunoglobulins) should help determine disease status and support decisions related to patient management.

Sections du résumé

BACKGROUND BACKGROUND
Since February 2020, Italian hospitals registered COVID-19 (COronaVIrus Disease 19) cases more often than the rest of the Europe. During this epidemic, health authorities requested swab tests, while seeking new patient paths.
METHODS METHODS
A dual laboratory approach was evaluated, consisting of patient care reports for viral RNA detection on swabs and rapid serological tests in 516 patients (192 symptomatic or paucisymptomatic and 324 asymptomatic).
RESULTS RESULTS
We found the molecular positive fraction equal to 12% (23/192) among symptomatic/paucisymptomatic (S/P) and 15.4% (50/324) in asymptomatic (As) sets. Among subsets, we observed serologically positive results, corresponding to 35% (8/23) for S/P and 38% (19/50) for As. Among molecular negative cases, we detected specific Immunoglobulin G or M (Ig G or Ig M) positivity in the S/P cohort equal to 6.6% (11/167) and 6% (15/246) in As cases. For indeterminate molecular results, we found S/P serological positivity equal to 100% (1/1) and 54% (13/24) in As patients. We found higher (p < 0.05) seropositivity in older patients (n = 8) among symptomatic and positives for viral RNA (n.23).
CONCLUSIONS CONCLUSIONS
It has been observed that a dual approach of serological and molecular tests detects a higher absolute number of disease cases in a pandemic context,which could improve monitoring and health surveillance efficacy. The age-related seropositivity frequency in this study, if confirmed, could enhance the validity of serological tests, especially in older patients.In these subjects, molecular positivity accompanied by serological positivity (distinct for M and G immunoglobulins) should help determine disease status and support decisions related to patient management.

Identifiants

pubmed: 32702365
pii: S0009-9120(20)30791-8
doi: 10.1016/j.clinbiochem.2020.07.002
pmc: PMC7371578
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

87-92

Informations de copyright

Copyright © 2020 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

J Adv Res. 2020 Mar 16;24:91-98
pubmed: 32257431
J Immunol. 2017 May 15;198(10):4046-4053
pubmed: 28373583
Lancet Infect Dis. 2018 Aug;18(8):e217-e227
pubmed: 29680581
J Korean Med Sci. 2020 Feb 24;35(7):e86
pubmed: 32080991
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Lancet. 2020 Apr 4;395(10230):1101-1102
pubmed: 32247384
Am J Infect Control. 2019 Oct;47(10):1167-1170
pubmed: 31128983
Int J Infect Dis. 2020 Apr;93:297-299
pubmed: 32147538
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Sensors (Basel). 2019 Sep 30;19(19):
pubmed: 31575036
Lancet Infect Dis. 2020 Apr;20(4):411-412
pubmed: 32105638
J Med Virol. 2020 May;92(5):512-517
pubmed: 32073157
J Med Virol. 2020 Sep;92(9):1518-1524
pubmed: 32104917
BMJ. 2020 Mar 22;368:m1163
pubmed: 32201376
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835
Rev Soc Bras Med Trop. 2012 Mar-Apr;45(2):163-7
pubmed: 22534985
J Korean Med Sci. 2020 Mar 23;35(11):e123
pubmed: 32193904
Mil Med Res. 2020 Apr 4;7(1):17
pubmed: 32245396
Am J Infect Control. 2018 Feb;46(2):165-168
pubmed: 28958446
Emerg Microbes Infect. 2020 Dec;9(1):747-756
pubmed: 32196430

Auteurs

Alessandro Pancrazzi (A)

Laboratory Medicine Department, Molecular and Clinical Pathology Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy. Electronic address: alessandro.pancrazzi@uslsudest.toscana.it.

Pasqualino Magliocca (P)

Laboratory Medicine Department, Serology Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Maria Lorubbio (M)

Laboratory Medicine Department, Hematology Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Guendalina Vaggelli (G)

Laboratory Medicine Department, Microbiology Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Angelo Galano (A)

Laboratory Medicine Department, Microbiology Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Manuela Mafucci (M)

Laboratory Medicine Department, Serology Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Diletta Duranti (D)

Laboratory Medicine Department, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Monica Cortesi (M)

Laboratory Medicine Department, Serology Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Erica Mazzeschi (E)

Laboratory Medicine Department, Serology Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Sara Fabbroni (S)

Laboratory Medicine Department, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Gianluca Viti (G)

Laboratory Medicine Department, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Alessandro Tartaglia Polcini (A)

Laboratory Medicine Department, Microbiology Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Emanuela Tripodo (E)

Laboratory Medicine Department, Quality Control Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Paola Sanchini (P)

Laboratory Medicine Department, Quality Control Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Silvana Gervino (S)

Laboratory Medicine Department, Molecular and Clinical Pathology Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Danilo Tacconi (D)

Internal Medicine Department, Infection Disease Section, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Simona Dei (S)

Health Management, Azienda USL Toscana Sudest, Tuscany, Italy.

Monica Mazzierli (M)

Laboratory Medicine Department, Serology Sector, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Antonio D'Urso (A)

General Direction, Azienda USL Toscana Sudest, Tuscany, Italy.

Agostino Ognibene (A)

Laboratory Medicine Department, Azienda USL Toscana Sudest, Ospedale San Donato, Arezzo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH